Science Explorer Back to mapMap

Most cited papers from Agile Therapeutics (United States)

Agile Therapeutics (United States)

What are the most cited papers from Agile Therapeutics (United States)?

The most cited paper from Agile Therapeutics (United States) is "A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models" (Elayne Chan-Penebre et al., 2015), with 561 citations. Next come "The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke" (177) and "Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase" (164).

Showing 35 of 35 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models Elayne Chan-Penebre et al. · Nature Chemical Biology 27 Apr 2015 561
2 The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke Karsten Ruscher, Mehrdad Shamloo, Mattias Rickhag et al. · Brain Open access 27 Jan 2011 177
3 Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase Anil K. Padyana, Stefan Größ, Lei Jin et al. · Nature Communications Open access 3 Jan 2019 164
4 Discoidin Domain Receptor-1a (DDR1a) Promotes Glioma Cell Invasion and Adhesion in Association with Matrix Metalloproteinase-2 Rosalyn R. Ram, Gustavo Lorente, Karoly Nikolich et al. · Journal of Neuro-Oncology 16 Sep 2005 124
5 Facile synthesis of chitin nanocrystals decorated on 3D cellulose aerogels as a new multi-functional material for waste water treatment with enhanced anti-bacterial and anti-oxidant properties Sreerag Gopi, Preetha Balakrishnan, Chandradhara Divya et al. · New Journal of Chemistry 2017 61
6 Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results Anita L. Nelson, Andrew M. Kaunitz, Robin Kroll et al. · Contraception Open access 28 Nov 2020 32
7 Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives Jeanne E. Loughlin, John D. Seeger, Patricia Mona Eng et al. · Contraception 13 Aug 2008 30
8 Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies Vishal Sachdeva, Yun Bai, Agis F. Kydonieus et al. · International Journal of Pharmaceutics 20 Dec 2012 30
9 Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial David F. Archer, Frank Z. Stanczyk, Arkady Rubin et al. · Contraception 8 Dec 2011 29
10 Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry Samuel Harold Sigal, Alpesh Amin, Joseph Chiodo et al. · Canadian Journal of Gastroenterology and Hepatology Open access 27 Sep 2018 26
11 Safety and tolerability of a new low-dose contraceptive patch in obese and nonobese women Andrew M. Kaunitz, David F. Archer, Daniel R. Mishell et al. · American Journal of Obstetrics and Gynecology 16 Sep 2014 20
12 Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise David F. Archer, Frank Z. Stanczyk, Arkady Rubin et al. · Contraception 15 Nov 2012 19
13 OSWG Recommended Approaches to the Nonclinical Pharmacokinetic (ADME) Characterization of Therapeutic Oligonucleotides Cindy L. Berman, Madeleine Antonsson, Sándor Bátkai et al. · Nucleic Acid Therapeutics Open access 17 Aug 2023 17
14 No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy Hwa-ping Feng, Zifang Guo, Luzelena Caro et al. · Clinical and Translational Science Open access 24 Jul 2018 14
15 Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel Marie L. Foegh, David F. Archer, Frank Z. Stanczyk et al. · Contraception Oct 2012 13
16 Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinylestradiol and levonorgestrel Frank Z. Stanczyk, Arkady Rubin, Lisa Flood et al. · Hormone Molecular Biology and Clinical Investigation 7 Mar 2011 13
17 The emerging role of obesity in short-acting hormonal contraceptive effectiveness Alison B. Edelman, James Trussell, Abigail R.A. Aiken et al. · Contraception Open access 18 Dec 2017 12
18 Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch Frank Z. Stanczyk, David F. Archer, Arkady Rubin et al. · Contraception 8 Dec 2012 8
19 Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model Frank Z. Stanczyk, David F. Archer, Lauren R. L. Lohmer et al. · PLoS ONE Open access 27 Dec 2022 4
20 Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants Keith E. Boundy, Yang Liu, Pratik R. Bhagunde et al. · Clinical Pharmacology in Drug Development 25 Mar 2020 4
21 Pridopidine treatment in ALS: subgroup analyses from the HEALEY ALS Platform trial Michal Geva, Y. Paul Goldberg, Melanie L. Leitner et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Open access 17 Dec 2025 3
22 Pridopidine treatment benefits in definite, probable, and early (<18mo onset) subjects with ALS in the HEALEY ALS Platform Trial Michal Geva, Y. Paul Goldberg, Melanie L. Leitner et al. · Neurotherapeutics Open access Jul 2025 1
23 Adhesion Evaluation of AG200-15: An Investigational Transdermal Contraceptive Delivery System Terrance Ocheltree, Janet Wittes, Jessica Case et al. · Advances in Therapy 10 Oct 2019 1
24 Complications of NSAIDs for patients over age 65. G E Farrar · PubMed 8 Mar 1990 1
25 An Automated Listener-Effort Measure for ALS Generalizes across Diverse Platforms and Protocols Esteban G. Roitberg et al. · Research Square PreprintOpen access 14 Jul 2026 0
26 In the phase 3 PROOF-HD trial, pridopidine shows consistent motor function improvements in Q-Motor measures, supporting Q-Motor as a predictive measure of long-term functional benefit and slower progression (cUHDRS) in Huntington disease Michal Geva, Ralf Reilmann, Robin Schubert et al. · Neurotherapeutics Open access Jul 2025 0
27 Supplementation of Griffonia simplicifolia and a Mushroom Blend Positively Influence Mood and Sleep Quality in Young Adults Melissa Riddell, Rachel Nye Venter, REC Wildman et al. · Current Developments in Nutrition Open access May 2025 0
28 IMPACT OF APPLICATION SITE AND BODY MASS INDEX ON ADHESION AND TOLERABILITY OF A LEVONORGESTREL/ETHINYL ESTRADIOL TRANSDERMAL CONTRACEPTIVE DELIVERY SYSTEM Andrew M. Kaunitz, Anita L. Nelson, Kurt Thomas Barnhart et al. · Fertility and Sterility Open access Sep 2021 0
29 High sigma-1 receptor (S1R) and very low dopamine 2/dopamine 3 receptor (D2/D3R) occupancy at clinically relevant doses of pridopidine in healthy volunteers (HV) and Huntington disease patients (HD): a F-18-Fluspidine and F-18-Fallypride PET study PM Meyer, ID Grachev, GA Becker et al. · Nuklearmedizin - NuclearMedicine Conference paper Apr 2020 0
30 Safety and side effects with investigational contraceptive patch use in women with and without hormonal contraceptive experience Paula M. Castaño, James A. Simon, B.A. Chen et al. · Fertility and Sterility Open access Sep 2018 0
31 Selected efficacy and bleeding/spotting outcomes from the secure trial: a phase 3 study of AG200-15, an investigational weekly transdermal contraceptive patch A. Nelson, Andrew M. Kaunitz, Robin Kroll et al. · Fertility and Sterility Open access Sep 2017 0
32 Results From the SECURE Trial, a Phase 3 Study of the AG200-15 Investigational Transdermal Contraceptive Patch [22A] Elizabeth I. O. Garner, Joseph Chiodo · Obstetrics and Gynecology May 2017 0
33 Perspectives on Clinical Therapeutics: a review of the past ten years and a look forward to the next decade. G E Farrar · PubMed 1988 0
34 Evaluation of exposure to ethinyl estradiol (EE) with a low dose combination transdermal contraceptive delivery system (AG200-15) compared to low-dose combination oral contraceptive D.F. Archer, Frank Z. Stanczyk, Arkady Rubin et al. · Fertility and Sterility Open access 27 Aug 2010 0
35 Safety and tolerability of the agile patch, a contraceptive patch with low-dose ethinyl estradiol (EE) and levonorgestrel (LNG), vs. combination oral contraceptives (COCs) in obese vs. non-obese women Andrew M. Kaunitz, David F. Archer, Marie L. Foegh · Fertility and Sterility Open access 25 Aug 2012 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.